Sign Out
Pregnancy: There are no or limited amount of data from the use of brimonidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see Pharmacology: Toxicology: Preclinical safety data under Actions). As a precautionary measure, it is preferable to avoid the use of Mirvaso during pregnancy.
Breast-feeding: It is unknown whether brimonidine/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Mirvaso should not be used during breast-feeding.
Fertility: Brimonidine did not present any special reproductive or developmental hazard in animal species.
Continue with Google